Skip to content

Duloxetine in dementia

Studying the effect of duloxetine on cognitive components and gamma-secretase enzyme levels in patients with cognitive impairment and depression

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20250920067298N1
Enrollment
72
Registered
2025-11-17
Start date
2025-12-01
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dementia. Alzheimers disease

Interventions

Intervention 1: Control group: In this group, 36 eligible patients were randomly selected. Participants received placebo capsules prepared by the pharmacist in charge of the study. The placebo consist

Sponsors

Ardabil University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to 80 Years

Inclusion criteria

Inclusion criteria: Age 65 to 80 years Being literate Alzheimer's disease and definitive diagnosis Consent to participate in the study

Exclusion criteria

Exclusion criteria: Severe cognitive impairment (MMSE score less than 10) severe heart failure (EF below 40)

Design outcomes

Primary

MeasureTime frame
Total score of Addenbrooke’s Cognitive Examination. Timepoint: Before the intervention begins and after the intervention ends. Method of measurement: Addenbrooke's test.;Gamma-secretase enzyme levels. Timepoint: Before the intervention begins and after the intervention ends. Method of measurement: ELISA test.;Working Memory Index. Timepoint: Before the intervention begins and after the intervention ends. Method of measurement: Wechsler Memory Test WMS-IV.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactOmid Ehsanzade

Ardabil University of Medical Sciences

omidehsanzadeh@yahoo.com+98 918 345 0654

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026